# FDA Approves Veppanu (vepdegestrant) for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

> fda · REPORTED · 2026-05-01

On May 1, 2026, the FDA approved Arvinas's vepdegestrant (Veppanu), a first-in-class heterobifunctional protein degrader, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following at least one prior line of endocrine therapy. The FDA simultaneously approved the Guardant360 CDx as a companion diagnostic to identify eligible patients.

About Veppanu (vepdegestrant) — Arvinas: Veppanu is a protein degrader therapy developed by Arvinas targeting estrogen receptor mutations in metastatic breast cancer patients who have progressed on endocrine therapy.

- Company: Veppanu (vepdegestrant) — Arvinas
- Sector: oncology
- Primary source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.